Fill-Finish Solutions That Grow With Your Program
Moving from clinical to commercial manufacturing? Learn how flexible fill-finish solutions, scalable capacity, and integrated support can help drive efficiency and readiness.
As demand for vaccines, biologics, and advanced therapies continues to grow, securing reliable fill-finish capacity remains an important consideration for successful product development and commercialization.
At the same time, manufacturing strategies need to remain aligned with the different stages of Clinical and commercial supply.
IDT Biologika supports customers throughout this journey with flexible aseptic fill-finish solutions for both vials and syringes. Our filling technologies are designed to accommodate changing program needs, from smaller clinical batches to high-speed commercial manufacturing, helping sponsors avoid unnecessary technology transfers and reduce operational complexity.
Our high-speed isolator filling lines combine advanced automation, robust process controls, and 100% camera-based inspection to ensure reliable and consistent production of proteins, vaccines, gene & Immune therapies, oncolytic viruses, monoclonal antibodies, biosimilars, and small molecules. With batch sizes of up to 500,000 vials and an annual capacity of up to 100 million vials, we provide the scalability needed to support evolving manufacturing needs.
As a fully integrated CDMO, IDT Biologika also offers expertise in process and analytical development, mammalian & microbial drug substance manufacturing, quality control, packaging, and supply chain support, enabling a seamless transition from development to commercial manufacturing.
Looking for a fill-finish strategy that supports your program at every stage? Contact our experts to learn more.